REGISTERED NUMBER: 07022086 (England and Wales)

Unaudited Financial Statements

for the Year Ended 31st March 2021

for

LONDON HAEMATOLOGY LIMITED

Contents of the Financial Statements for the year ended 31st March 2021

	Page
Company Information	1
Statement of Financial Position	2
Notes to the Financial Statements	4
Chartered Accountants' Report	7

LONDON HAEMATOLOGY LIMITED

Company Information for the year ended 31st March 2021

DIRECTORS: Dr R Jan-Mohamed

Dr R Kaczmarski Dr M N Potter Prof J G Gribben

REGISTERED OFFICE: Suffolk House

George Street Croydon Surrey CRO 0YN

REGISTERED NUMBER: 07022086 (England and Wales)

ACCOUNTANTS: Simpson Wreford & Partners

Chartered Accountants

Suffolk House George Street Croydon Surrey CRO OYN

Statement of Financial Position 31st March 2021

	31.3	.21	31.3.	.20
Notes	£	£	£	£
4		-		-
5		55,042		75,642
		55,042		75,642
6	685,321		737,512	
	785,711		383,471	
	1,471,032		1,120,983	
7	526,368		270,620	
		944,664		850,363
		999,706		926,005
		100		100
		999,606		925,905
		999,706		926,005
	4 5	Notes £ 4 5 6 685,321 785,711 1,471,032	4 5 55,042 55,042 6 685,321	Notes £ £ £ £ 4 5 5 55,042 55,042 6 685,321 785,711 1,471,032 7 526,368 944,664 999,706 100 999,606

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2021 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Statement of Financial Position - continued 31st March 2021

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 5th April 2021 and were signed on its behalf by:

Prof J G Gribben - Director

Dr R Jan-Mohamed - Director

Dr R Kaczmarski - Director

Dr M N Potter - Director

Notes to the Financial Statements for the year ended 31st March 2021

1. STATUTORY INFORMATION

London Haematology Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill

Goodwill, being the amount paid in connection with the acquisition of a business in 0, is being amortised evenly over its estimated useful life of nil years.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost Computer equipment - 25% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Page 4 continued...

Notes to the Financial Statements - continued for the year ended 31st March 2021

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2020 - 11).

4	INTANGIE	RI E FIXED	ASSETS

4.	INTANGIBLE FIXED ASSETS				Goodwill £
	COST				
	At 1st April 2020				2 200 200
	and 31st March 2021				3,200,000
	AMORTISATION				
	At 1st April 2020 and 31st March 2021				2 200 000
	NET BOOK VALUE				3,200,000
	At 31st March 2021				
	At 31st March 2020				
	At 515t Watch 2020				
5.	PROPERTY, PLANT AND EQUIPMENT				
	,		Fixtures		
		Plant and	and	Computer	
		machinery	fittings	equipment	Totals
		£	£	£	£
	COST				
	At 1st April 2020				
	and 31st March 2021	307,390	700	6,721	314,811
	DEPRECIATION				
	At 1st April 2020	233,443	700	5,026	239,169
	Charge for year	<u>19,708</u>		892	20,600
	At 31st March 2021	253,151	700	5,918	259,769
	NET BOOK VALUE				
	At 31st March 2021	<u>54,239</u>		803	55,042
	At 31st March 2020	<u>73,947</u>		1,695	<u>75,642</u>
6.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR				
٥.				31.3.21	31.3.20
				£	£
	Trade debtors			655,20 1	713,398
	Prepayments			30,120	24,114
	• •			685,321	737,512

Page 5 continued...

Notes to the Financial Statements - continued for the year ended 31st March 2021

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.3.21	31.3.20
	£	£
Тах	300,807	161,927
Social security and other taxes	7,654	16,660
Other creditors	49,580	69,493
Directors' loan accounts	165,577	20,290
Accrued expenses	2,750	2,250
	526,368	270,620

Chartered Accountants' Report to the Board of Directors on the Unaudited Financial Statements of London Haematology Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Statement of Financial Position. Readers are cautioned that the Statement of Comprehensive Income and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of London Haematology Limited for the year ended 31st March 2021 which comprise the Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of London Haematology Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of London Haematology Limited and state those matters that we have agreed to state to the Board of Directors of London Haematology Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than London Haematology Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that London Haematology Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of London Haematology Limited. You consider that London Haematology Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of London Haematology Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Simpson Wreford & Partners Chartered Accountants Suffolk House George Street Croydon Surrey CRO 0YN

5th April 2021

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.